Thu, 08 Jun 2023 20:48:05 -0700WeeblyThu, 11 May 2017 07:00:00 GMThttp://beloteca.com/news/beloteca-moves-to-a-larger-facility-in-san-diegoSAN DIEGO, May 11, 2017 /PRNewswire/ -- Beloteca, Inc., a specialty pharmaceutical company focused on the development of sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations, announced today that it has relocated its product development laboratories and corporate headquarters to a new larger location in San Diego, California.  The unification of the headquarters and laboratories will provide increased communication and collaboration between development and the other departments resulting in more efficient development of products.

"We are excited to have found this new location as it will enable Beloteca to continue to grow and internalize development over the next several years," said Fred Defesche, Chief Executive Officer of Beloteca, Inc. "The new space is ideal because it allows us to acquire additional space after obtaining approval of our first products without being encumbered by excess expenses while we are in our startup phase."

The new facility currently spans more than 3,500 square feet and will expand to over 6,000 square feet.  The larger space allows Beloteca's to increase its in-house product development capabilities and hire more employees in formulation and analytical development. 

Beloteca is a privately held specialty pharmaceutical company.  Beloteca's primary focus is to develop, obtain regulatory approval and out license sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations. Beloteca currently has an active development pipeline with more than 15 pharmaceutical products in various stages of development.  For additional information about the Company, visit the Company's web site at www.beloteca.com.

For further information, please contact Fred Defesche at 512-669-8765 or via email fdefesche@beloteca.com.
]]>Tue, 26 Jan 2016 00:37:24 GMThttp://beloteca.com/news/beloteca-ceo-interviewed-in-ceocfo-magazineBeloteca is pleased to announce that it's CEO, Fred Defesche, was interviewed in CEO/CFO Magazine.  To find the interview click here.]]>Tue, 27 Oct 2015 19:53:10 GMThttp://beloteca.com/news/beloteca-announces-opening-of-new-laboratory-in-san-diegoSAN DIEGO, Oct. 27, 2015 /PRNewswire/ -- Beloteca, Inc., a specialty pharmaceutical company focused on the development of sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations, today announced that it has opened its product development laboratory in San Diego, California. 

"This new laboratory helps Beloteca achieve its mission of developing multiple products per year," said Fred Defesche, Chief Executive Officer of Beloteca, Inc. "It also allows Beloteca to take greater control over project timelines and the development process."

"The new laboratory establishes Beloteca's in-house product development capabilities allowing the evaluation of development projects prior to initiating full development creating a more nimble and aggressive approach to project selection.  Additionally, the new laboratory will be used for many of Beloteca's analytical and formulation development activities enabling Beloteca to develop many of its products in house," stated Dorla Mirejovsky, Chief Scientific Officer of Beloteca. 

Beloteca is a privately held specialty pharmaceutical company.  Beloteca's primary focus is to develop and obtain regulatory approval for sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations. We target niche and difficult to manufacture products. For additional information about the Company, visit the Company's web site at www.beloteca.com.

For further information, please contact Fred Defesche at 512-669-8765 or via email fdefesche@beloteca.com.

]]>Mon, 24 Aug 2015 16:40:23 GMThttp://beloteca.com/news/beloteca-appoints-dorla-mirejovsky-as-chief-scientific-officerSAN DIEGO, Aug. 24, 2015 /PRNewswire/ -- Beloteca, Inc., a specialty pharmaceutical company focused on the development of sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations, is pleased to announce the appointment of Dorla Mirejovsky, Ph.D. as Chief Scientific Officer. 

"We are excited to have Dorla join Beloteca; she is a terrific addition to the team we are building," stated Fred Defesche, Chief Executive Officer of Beloteca, Inc. "Dorla's expertise in developing sterile based pharmaceuticals strengthens the capabilities of Beloteca."

Dr. Mirejovsky brings more than 30 years of pharmaceutical development experience to Beloteca.  Dr. Mirejovsky has contributed to the development and commercialization of more than 60 products.  She has served in product development roles of increasing responsibility for leading companies such as Allergan, Isis Pharmaceuticals, Sicor Pharmaceuticals, Spectrum Pharmaceuticals and Avrio Biopharma.  Dorla joins Beloteca from Avrio Biopharma where she was responsible for the formulation department which supported more than 30 formulation products for various pharmaceutical clients. 

"I am very excited to join Beloteca, and look forward to contributing to the development of Beloteca's business," stated Dorla Mirejovsky, Chief Scientific Officer of Beloteca. 

Beloteca is a privately held specialty pharmaceutical company.  Beloteca's primary focus is to develop and obtain regulatory approval sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations. We target niche and difficult to manufacture products. For additional information about the Company, visit the Company's web site at www.beloteca.com.

For further information, please contact Fred Defesche at 512-669-8765 or via email at fdefesche@beloteca.com.

]]>Sun, 14 Jun 2015 21:21:23 GMThttp://beloteca.com/news/cphi-2015-in-madridBeloteca, Inc. is pleased to announce that we will be attending CPhI worldwide occurring from October 13, 2015 through October 15, 2015 in Madrid Spain.  CPhI brings together the global pharmaceutical community, connecting buyers and suppliers at exhibitions, conferences and online to identify business opportunities.

If you would like to arrange a meeting, please contact us at busdev@beloteca.com.]]>